Clinical Trials

The purpose of this study is to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules.

The purpose of this study is to describe in detail the smoking history in a population of acute or prior cerebrovasculqar accident (CVA) patients and identify those who qualify for lung cancer screening by criteria outlined by three separate organizations.

The purpose of this study is to determine 3- and 5-year disease-free survival (DFS) among patients undergoing pulmonary segmentectomy for lung cancer. Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.

The purpose of this study is to determine the sensitivity and specificity of a blood test (DLCST) for the detection of lung cancer in a screening setting using the reference of Chest CT screening and a histologic diagnosis of lung cancer.

The purpose of this study is to assess the current rate of adherence to incidental lung nodule management and lung cancer screening guidelines in at-risk lung cancer patients identified from chart review.

Imbio is developing a Smoking Cessation Report (Report) that includes data analysis from a CT lung cancer screening exam. This randomized controlled (RCT) trial will clinically validate the Report's effectiveness at motivating smokers to call a Quitline.

The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.